Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07092566 · ClinicalTrials.gov registry record · Phase 3
R.E.C.K vs Exparel in Robotic Nephrectomy
A Phase 3 study of Pain Management and Renal Carcinoma, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 170
- Enrollment target
- 1
- Study location
NCT07092566: Recruiting Phase 3 study of Pain Management and Renal Carcinoma, sponsored by Wake Forest University Health Sciences.
NCT07092566 is a Phase 3 study of Pain Management and Renal Carcinoma that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 170 participants, above the 149-participant average among 31 other Pain Management trials with a reported enrollment target (14% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07092566, a Phase 3 study of Pain Management and Renal Carcinoma, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 170 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will evaluate post operative Numerical Rating Score (NRS) pain scores, post operative pain medication intake (opioids and over-the-counter pain medicines) and length of stay across the two patient cohorts. The findings will help to inform whether the increased cost of Exparel when compared to R.E.C.K is justified.
Primary Outcome
Assess pain intensity (evaluated by NRS) after surgery on the as response to the prompt: "On a scale of 0 to 10, where 0 = no pain and 10 = worst possible pain, how much pain are you having right now?" The AUC will be derived for each participant from self-reported pain scores and will be summarized by treatment group. Generalized linear models with main effect of treatment will be estimated to test for significant differences in AUC between the arms.
Conditions Studied
Interventions
- DRUG Ketorolac
- DRUG Epinephrine
- DRUG Exparel
- DRUG Ropivacaine HCL
- DRUG Clonidine HCL
Study Locations (1)
North Carolina
- Levine Cancer - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2025-11-14 |
| Est. Completion | 2027-10 |
| Phase | Phase 3 |
What NCT07092566 shows while recruiting
NCT07092566 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, above the 149-participant average among 31 other Pain Management trials with a reported enrollment target (14% higher).
The record links to 3 conditions, with Pain Management appearing as the primary indexed condition, and to 5 interventions - of which Ketorolac is the first listed.
NCT07092566 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT07092566 about?
NCT07092566 is a clinical study titled "R.E.C.K vs Exparel in Robotic Nephrectomy". The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will evaluate post operative Numerical Rating Score (NRS) pain sco...
What is the current status of trial NCT07092566?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 170 participants. The study started on 2025-11-14. Estimated completion is 2027-10.
What conditions does trial NCT07092566 study?
This clinical trial studies the following conditions: Pain Management, Renal Carcinoma, Nephrectomy / Methods.
What interventions are being tested in trial NCT07092566?
The interventions under investigation include: Ketorolac (DRUG), Epinephrine (DRUG), Exparel (DRUG), Ropivacaine HCL (DRUG), Clonidine HCL (DRUG).
Who is sponsoring clinical trial NCT07092566?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07092566 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain Management
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07092566's enrollment target sits among peer trials
170 10th of 31 higher than 22 of 31 other Pain Management trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain Management trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Suzetrigine in Total Hip Arthroplasty
RECRUITING · Phase 3
-
Tramadol Versus Placebo and Morphine in the Management of Post-Operative Pain Abdominoplasty
ACTIVE NOT RECRUITING · Phase 3
-
Patient Controlled Epidural Analgesia Versus Intravenous Patient Controlled Analgesia for Post-Operative Pain Control in Patients Undergoing Elective Liver Resection
ACTIVE NOT RECRUITING · Phase 3
-
Tramadol Versus Placebo in the Management of Postoperative Pain Following Bunionectomy
COMPLETED · Phase 3
-
Phase 3 Adductor Canal Block With EXPAREL in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty
COMPLETED · Phase 3
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI